Group items tagged

For Dr. John Evans, growing a strong biotechnology industry is much the same: cities must provide a nurturing environment where science and business can thrive together.

That's why Evans, former president of the University of Toronto and current chairman of Torstar Corp., is spearheading the $345-million Medical and Related Science initiative, or MaRS--a petri dish of sorts for commercializing science research. "A lot of intellectual property is being commercialized outside Canada," says Evans. "I think we've been slow in realizing just how important technology developments are to the economic future of the country. MaRS is an attempt to give this a kick into a higher gear." The centrepiece of the MaRS plan, which will officially launch May 12, is a 1.3-million-square-foot, five-building complex in downtown Toronto that will provide office and lab space for small and medium-size companies and incubators, including the not-for-profit Toronto Biotechnology Commercialization Centre. While Evans is reluctant to limit its scope, MaRS will generally focus on health-related technologies, from new drugs and genetic treatments to medical devices and imaging software. Branded a "convergence centre," it will also house a careful mix of support services: intellectual property lawyers, accountants, marketing experts, government funding organizations and venture capital financiers. Plus, start-ups will have access to all the latest equipment on site. For instance, MaRS is in talks with MDS Sciex to supply mass spectrometers, used in proteomics research.

But MaRS will be more than just a New Economy real estate development. Evans's intention is to funnel tenants' rent money into services--such as entrepreneurship seminars and angel-matching programs--that MaRS will offer to the broader biotech community. That's why MaRS's location is key: the centre will be built in the heart of what Toronto has dubbed the "Discovery District," a two-square-kilometre chunk of the downtown core, encompassing U of T and four major hospitals. From there, MaRS hopes to act as a network hub across Ontario, with links to research-intensive universities. "None of them," says Evans, "have the critical mass to put it all together on their own."

MaRS aggregates the discovery pipelines of its member institutions, which include three universities, 10 academic teaching hospitals, and the Ontario Institute for Cancer Research.

MaRS is another good example. Located in the heart of downtown Toronto, the MaRS facility is less than a mile from five major teaching hospitals, the Ontario legislature, and the University of Toronto. More than two dozen research institutes and Toronto’s financial district are also nearby.

Consequently, MaRS is a vertical incubator, with a wide variety of companies and stages of development. That mix helps companies better understand the conditions that foster growth. MaRS is home to more than 65 organizations, including The Hospital for Sick Children, the Ontario Institute for Cancer Research, Merck Frosst Canada, the McEwen Centre for Regenerative Medicine, Celtic House Venture Partners, AIM Therapeutics, and AstraZeneca Canada.